KRAS mutational analysis in ductal adenocarcinoma of the pancreas and its clinical significance

Umberto Miglio, Alberto Oldani, Rosanna Mezzapelle, Claudia Veggiani, Alessia Paganotti, Marcello Garavoglia, Renzo Boldorini

Research output: Contribution to journalArticle

Abstract

Mutations of KRAS are detectable in 70-90% of pancreatic duct adenocarcinomas (PDAC), using direct sequencing. We used a highly sensitive molecular method in order to investigate: (a) the frequency and prognostic significance of different KRAS mutations and, (b) whether the presence of KRAS mutations in histologically-negative resection margins of PDAC could explain local tumor recurrence after surgery.Twenty-seven patients with histologic diagnosis of PDAC, radical pancreaticoduodenectomy and histologically-negative margins were evaluated. KRAS mutations were searched for mutant-enriched PCR in tumor and negative resection margins.KRAS mutations were detected in 85.2% of the cases; the most frequent mutation was G12D (48.1%). Shorter OS was found in patients with G12D (25 months; 95% CI, 20.5-29.5), vs patients with other mutations (31.5 months; 95% CI, 25.6-37.1) (N.S.). KRAS mutation in histologically-negative margins was detected in one patient who died of locoregional recurrence; six patients had tumor recurrence but no mutations in surgical margins.The high frequency of KRAS mutations suggests a search for KRAS status to improve the diagnosis in suspected cases; the G12D mutation could be related to poor prognosis, but without statistical significance. No correlation was found between the frequency of cancer recurrence and KRAS mutations in surgical margins.

Original languageEnglish
Pages (from-to)307-311
Number of pages5
JournalPathology Research and Practice
Volume210
Issue number5
DOIs
Publication statusPublished - 2014

Keywords

  • Adenocarcinoma
  • KRAS mutations
  • Pancreas

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Cell Biology
  • Medicine(all)

Fingerprint Dive into the research topics of 'KRAS mutational analysis in ductal adenocarcinoma of the pancreas and its clinical significance'. Together they form a unique fingerprint.

  • Cite this

    Miglio, U., Oldani, A., Mezzapelle, R., Veggiani, C., Paganotti, A., Garavoglia, M., & Boldorini, R. (2014). KRAS mutational analysis in ductal adenocarcinoma of the pancreas and its clinical significance. Pathology Research and Practice, 210(5), 307-311. https://doi.org/10.1016/j.prp.2014.01.011